Karen Barnett

Dr. Karen Barnett


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
KBKaren Barnett
Karen Barnett
GCGavin Clark
Gavin Clark
RSRobert J. C. Steele
Robert J. C. Steele
CFCallum Fraser
Callum Fraser
Multimorbidity is the major cause of ill-health and premature death in developed countries. The ability to identify individuals at risk of developing chronic disease, particularly multimorbidity, reliably, and simply, and to identify undiagnosed disorders, is vital to reducing the global burden of disease. This narrative review, the first of recent studies, demonstrates that raised faecal haemoglobin concentration (f-Hb) is associated with increased all-cause and cause-specific mortality and with longer-term conditions including diabetes, hypertension, cardiovascular disease, and psoriasis, and with probable intake of particulate matter. We and others have hypothesized that elevated f-Hb (measured using a faecal immunochemical test) has considerable potential to identify individuals at risk of, or who already have, early stage, undiagnosed chronic disease. If f-Hb does prove to be an effective biomarker for chronic disease and multimorbidity, individuals with detectable f-Hb, but without an obvious source of gastrointestinal blood loss, could benefit from further assessment and early intervention. To test this hypothesis rigorously, longitudinal data-linkage methodology is required linking colorectal cancer screening data, and data on patients presenting with lower gastrointestinal symptoms, with routinely collected health information.

20 March 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
CGChristopher H. Grant
Christopher H. Grant
HWHeather Walker
Heather Walker
KBKaren Barnett
Karen Barnett
PMPatrick B. Mark
Patrick B. Mark
LCLesley A. Colvin
Lesley A. Colvin
SBSamira Bell
Samira Bell
Multimorbidity is the presence of two or more long-term medical conditions. Chronic pain affects more than half of people with multimorbidity, and optimal treatment strategies are unknown. We aimed to quantify the risk of adverse outcomes from the following analgesics: opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and gabapentinoids in adults with multimorbidity. The review was registered on PROSPERO (CRD42023462592). We searched Medline, CINAHL, Web of Science, Embase, and CENTRAL for studies reporting analgesic-related harms in people with multimorbidity or the impact of multimorbidity on harms in adults exposed to analgesics. Two researchers independently screened titles/abstracts, completed full-text reviews, extracted data, and assessed risk of bias using the Newcastle-Ottawa scale. Studies were synthesised narratively, grouping by analgesic class and direction of effect. We screened 6690 records and 344 full texts, with 27 studies included (n=2 671 958 patients). Studies were heterogenous, with variable quality (high risk of bias, n=11). Most studies on opioids reported adverse outcomes (12/16). Opioid use compared with non-use was associated with increased mortality in adults with multimorbidity. Multimorbidity was associated with opioid overdose and death among adults prescribed opioids for pain. Half of studies of NSAIDs reported adverse outcomes (6/11) including gastrointestinal bleeding. Only one study assessed gabapentinoids which found an association with delirium and pneumonia, but not mortality in people with multimorbidity. There is evidence of harms associated with opioids in adults with multimorbidity, including overdose and increased mortality. There is a lack of evidence on gabapentinoids. Further research is required to understand optimal analgesic management in people with multimorbidity. PROSPERO (CRD42023462592).

22 October 2024 in British Journal of Anaesthesia
Verified
Journal Article
Open access
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
MKMia Koponen
Mia Koponen
KBKaren Barnett
Karen Barnett
BSBlair Smith
Blair Smith
THTim G. Hales
Tim G. Hales
LCLesley A. Colvin
Lesley A. Colvin
There is well-established evidence linking adverse childhood experiences (ACEs) and chronic pain in adulthood. It is less clear how ACE exposure might influence the response to chronic pain treatment. In this systematic review, we synthesise the literature assessing the impact of ACE exposure on outcomes relating to the use, benefits, and harms of analgesic medications (analgesia-related outcomes). We searched seven databases from inception to September 26, 2023, for studies investigating adverse events in childhood (<18 yr) and any analgesia-related outcome during adulthood (≥18 yr). Title/abstract screening, full-text review, data extraction, and risk of bias assessment were performed independently by two authors. Given the high degree of study heterogeneity, a narrative synthesis was performed. From 7531 records, 66 studies met inclusion criteria, involving 137 395 participants. Analgesia-related outcomes were classed into six categories: use of analgesics (n=12), analgesic side-effects (n=4), substance misuse (n=45), lifetime drug overdose (n=2), endogenous pain signalling (n=4), and other outcomes (n=2). No studies assessed the effect of ACE exposure on the potential benefits of analgesics. ACE exposure was associated with greater use of analgesic medication, higher incidence of analgesic medication side-effects, greater risk and severity of substance misuse, greater risk of drug overdose, and greater risk of attempted suicide in opioid dependency. Adverse childhood experience exposure is associated with poor analgesia-related outcomes, so individual assessment adverse childhood experiences is important when considering the treatment of chronic pain. However, significant gaps in the literature remain, especially relating to the use and harms of non opioid analgesics. CRD42023389870 (PROSPERO).

3 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
BABukola G Adekanmi
Bukola G Adekanmi
CMCharis A Marwick
Charis A Marwick
HWHuan Wang
Huan Wang
KBKaren Barnett
Karen Barnett
Background: Antimicrobial resistance and depression are leading causes of global morbidity and mortality. Depression is the most common mental health disorder, with antidepressant use doubling between 2000 and 2022. Infectious diseases are increasingly difficult to treat due to some antimicrobial agents becoming ineffective. Antibiotic use is known to drive resistance in clinical bacterial infections, and laboratory studies have found that antidepressants have antibiotic properties, affecting the microbiota and stimulating mechanisms that help certain bacteria resist antibiotics. Aim: To map and evaluate existing literature on the association between antidepressants and antimicrobial resistance. Methods: This scoping review followed the modified Arksey and O’Malley’s framework. Systematic searches of MEDLINE, PubMed, Scopus and grey literature were conducted. Studies were screened for eligibility, assessed for risk of bias using ToxRTool, and analysed using a narrative synthesis. Results: Ten articles met the inclusion criteria, eight laboratory studies and two reviews. Studies reported that exposure of bacteria to antidepressants increased antibiotic resistance. There were no eligible human or animal microbiome, or population studies. Conclusion: This scoping review highlights the need for microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections have implications for real-world practice, impacting clinical guidelines and patient care. Key Messages: What is already known on this topic: Depression and antibiotic resistance are both critical global health concerns. The use of antidepressant drugs is increasing and there is a growing body of laboratory evidence demonstrating that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), exhibit antimicrobial activity against bacteria. What this study adds: This scoping review maps and synthesizes existing evidence on associations between antidepressants and antimicrobial resistance, including mechanisms involved, and identifies important gaps in the literature. The eight primary research studies included were all laboratory-based, bacterial studies. All found that exposure of bacteria to antidepressant drugs increased antibiotic resistance. There were no eligible human or animal microbiome studies, or human clinical or population studies. How this study might affect research, practice or policy: This scoping review highlights the need for more microbiome, clinical, and population studies. Associations between antidepressants and antibiotic resistance in clinical infections could have implications for real-world practice, impacting clinical guidelines and patient care.

2 June 2026 in medRxiv
Verified
Preprint
Open access
PDF file
KBKaren Barnett
Karen Barnett
LWLinda Williams
Linda Williams
DWDavid Weller
David Weller
SMStewart Mercer
Stewart Mercer
BGBruce Guthrie
Bruce Guthrie
CCChristine Campbell
Christine Campbell
Multimorbidity, the co-existence of two or more long-term conditions, is up to three times more prevalent among people with cancer than in the general population and is associated with poorer survival, particularly for cancers with a more favourable prognosis such as colorectal cancer. In Scotland, multimorbidity is the norm among older adults, emerges earlier in socioeconomically deprived populations, and may contribute to comparatively low cancer survival rates. Despite this, the influence of multimorbidity on the colorectal cancer pathway remains poorly understood. We conducted a Scottish data-linkage study of adults diagnosed with colorectal cancer between 2010 and 2014, linking the Scottish Cancer Registry to national prescribing, hospital admissions, death registration, and bowel screening datasets. Prescribing data were used to derive overall and system-specific comorbidity measures as a proxy for multimorbidity and active disease burden. Associations with stage at diagnosis, treatment, survival, and screening uptake were examined using logistic regression and Cox proportional hazards models adjusted for demographic and clinical covariates. Among 19,043 patients, 87% had at least one prescribing-based comorbidity, most commonly cardiovascular, nervous system, and gastrointestinal conditions. Overall comorbidity burden was not associated with stage at diagnosis, although laxative-related prescribing was associated with later-stage disease. Increasing comorbidity burden reduced the likelihood of receiving any treatment and surgery, while associations varied across system-specific comorbidities. Higher comorbidity burden was also associated with increased all-cause and colorectal cancer-specific mortality, particularly among patients with respiratory, nervous system, and haematological/nutritional conditions. Screening uptake was not associated with overall comorbidity burden but did differ by system-specific comorbidity. Prescribing-based multimorbidity was highly prevalent and strongly associated with treatment patterns and mortality among patients with colorectal cancer. System-specific multimorbidity measures provided greater discrimination than overall morbidity counts, highlighting the importance of considering distinct multimorbidity profiles when assessing cancer pathways and designing targeted interventions for optimising treatment and survival.